Matcha: The Japanese tea taking over the world
It is heralded for its unique taste, health benefits, and photogenic appeal, rich antioxidant levels and calming properties which have captured the interest of wellness enthusiasts and social media influencers alike.
However, as global demand soars beyond Japan's ability to keep pace, matcha remains synonymous with quality craftsmanship and Japanese tradition.
Matcha is the new drink of choice at hip cafes worldwide, but Japanese producers are struggling to keep up with soaring demand for the powdered green tea.
Here's what you need to know about the drink beloved of weekend treat-seekers and 'wellness' influencers:
What is matcha?
The word matcha means 'ground tea' in Japanese and comes in the form of a vivid green powder that is whisked with hot water and can be added to milk to make a matcha latte.
Green tea was introduced to Japan from China in the early ninth century, and was first used for medicinal purposes.
Matcha came much later, in 16th century Kyoto -- part of the tea ceremony tradition developed by tea master Sen no Rikyu.
Today, there are different grades of matcha quality, from 'ceremonial' to 'culinary' types used in baking.
How is it produced?
Matcha is made from leaves called 'tencha', which are grown in the shade in the final weeks before their harvest to concentrate the flavour, colour and nutrients.
This 'requires the construction of a complex structure with poles and a roof to filter the light', explained Masahiro Okutomi, a tea producer in Sayama, northwest of Tokyo.
Tencha leaves, rich in chlorophyll and L-theanine, a compound known for its relaxing effects, are hand-picked and deveined, then steamed, dried and ground between two stone mills to produce an ultra-fine powder.
AFP
It can take up to an hour to produce just 40 grams (1.4 ounces) of matcha - making the powder on average twice as expensive to produce as standard green tea leaves.
What are its benefits?
Many drink matcha for its rich grass-like taste, but others are drawn to the drink's nutritional properties.
It is rich in antioxidants, and can aid concentration because of its caffeine content: one cup contains on average 48 milligrams, slightly less than a drip coffee but nearly twice as much as a standardly brewed green tea.
'Matcha is often seen as being good for your health,' said Shigehito Nishikida, manager of Tokyo tea shop Jugetsudo.
Why is it so popular?
Japan produced 4 176 tonnes of matcha in 2023 - a huge increase from the 1 430 tonnes in 2012.
More than half of the powder is exported, according to the agriculture ministry, mostly to the United States, Southeast Asia, Europe, Australia and the Middle East.
Millions of videos on TikTok, Instagram and YouTube demonstrate how to make photogenic matcha drinks or choose a traditional 'chasen' bamboo whisk.
READ |
'I feel like Gen Z really drove this enthusiasm for matcha, and they heavily relied on social media to do so,' Stevie Youssef, a 31-year-old marketing professional, told AFP at a matcha bar in Los Angeles.
Matcha can also be used in cooking, extending its appeal to others aside from tea lovers.
'Some customers simply enjoy drinking it, others like preparing it themselves. And of course, many buy it as a gift - Japanese matcha is always appreciated,' said Jugetsudo's Nishikida.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Study Reveals Turning Point When Your Body's Aging Accelerates
The passage of time may be linear, but the course of human aging is not. Rather than a gradual transition, your life staggers and lurches through the rapid growth of childhood, the plateau of early adulthood, to an acceleration in aging as the decades progress. Now, a new study has identified a turning point at which that acceleration typically takes place: at around age 50. After this time, the trajectory at which your tissues and organs age is steeper than the decades preceding, according to a study of proteins in human bodies across a wide range of adult ages – and your veins are among the fastest to decline. "Based on aging-associated protein changes, we developed tissue-specific proteomic age clocks and characterized organ-level aging trajectories. Temporal analysis revealed an aging inflection around age 50, with blood vessels being a tissue that ages early and is markedly susceptible to aging," writes a team led by scientists from the Chinese Academy of Sciences. "Together, our findings lay the groundwork for a systems-level understanding of human aging through the lens of proteins." Related: Study Finds Humans Age Faster at 2 Sharp Peaks – Here's When Humans have a remarkably long lifespan compared to most other mammals, but it comes at some costs. One is a decline in organ function, leading to a rise in risk of chronic disease as the years mount up. We don't have a very good understanding of the patterns of aging in individual organs, so the researchers investigated how proteins in different tissues change over time. They collected tissue samples from a total of 76 organ donors between the ages of 14 and 68 who had died of accidental traumatic brain injury. These samples covered seven of the body's systems: cardiovascular (heart and aorta), digestive (liver, pancreas, and intestine), immune (spleen and lymph node), endocrine (adrenal gland and white adipose), respiratory (lung), integumentary (skin), and musculoskeletal (muscle). They also took blood samples. The team constructed a catalogue of the proteins found in these systems, taking careful note of how their levels changed as the ages of the donors increased. The researchers compared their findings to a database of diseases and their associated genes, and found that expressions of 48 disease-related proteins increased with age. These included cardiovascular conditions, tissue fibrosis, fatty liver disease, and liver-related tumors. The most stark changes occurred between the ages of 45 and 55, the researchers found. It's at this point that many tissues undergo substantial proteomic remodeling, with the most marked changes occurring in the aorta – demonstrating a strong susceptibility to aging. The pancreas and spleen also showed sustained change. To test their findings, the researchers isolated a protein associated with aging in the aortas of mice, and injected it into young mice to observe the results. Test animals treated with the protein had reduced physical performance, decreased grip strength, lower endurance, and lower balance and coordination compared to non-treated mice. They also had prominent markers of vascular aging. Previous work by other researchers showed another two peaks in aging, at around 44, and again at around 60. The new result suggests that human aging is a complicated, step-wise process involving different systems. Working out how aging is going to affect specific parts of the body at specific times could help develop medical interventions to make the process easier. "Our study is poised to construct a comprehensive multi-tissue proteomic atlas spanning 50 years of the entire human aging process, elucidating the mechanisms behind proteostasis imbalance in aged organs and revealing both universal and tissue-specific aging patterns," the researchers write. "These insights may facilitate the development of targeted interventions for aging and age-related diseases, paving the way to improve the health of older adults." The research has been published in Cell. Related News Putting Makeup on Children Could Risk Their Health, Study Shows New Kind of Dental Floss Could Replace Vaccine Needles, Study Finds World's Most Common Pain Relief Drug May Induce Risky Behavior, Research Suggests Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Android Authority
2 hours ago
- Android Authority
Watch and learn, Samsung: This Galaxy Ring competitor now predicts your chances of falling sick
Kaitlyn Cimino / Android Authority TL;DR Circular's smart ring is getting a new Immunity Index that measures your defense against diseases. It accounts for your vitals and gives you a rating on a scale of 0–8. The feature is rolling out to the companion app for the first-gen Circular Ring and will be available for the Ring 2, which is expected to be available soon. Even though the smart ring market is still niche, the entry of big players like Samsung with its Galaxy Ring has set it into motion. Besides already established brands like Oura and (relatively) new entrants like Samsung, a host of smaller brands are looking to benefit from this momentum. Circular, one of these brands, is making noise with unusual (for a smart ring) features such as blood pressure and non-invasive sugar level monitoring right from your finger. While we await its newer generation, Circular's existing model is gaining new insights that predict before you fall sick. The first-generation Circular Ring now takes into account vital health metrics, including HRV or Heart Rate Variability, resting heart rate, irregular breathing patterns during sleep, and variations in skin temperature. This data is consolidated into an Immunity Index, which, Circular says, is designed to indicate a user's 'readiness to fight off diseases.' Based on continuous reading of these metrics, the Immunity Index gives a rating out of eight to quantify users' immunity. It will also warn users of their chances of falling sick, similar to what the Apple Watch does through its Vitals app. My colleague Rita El Khoury also discovered a similar feature worked well on her Oura Ring, which notified her before she fell sick. However, both Galaxy Watch and Pixel Watch currently lack features to detect signs of illness. If you're wondering why Circular chose a rating out of eight instead of ten, it is because it has five tiers based on definite ratings, rather than a more descriptive scale. Continuous details these ratings as follows: 8/8: All Clear, where all your metrics lie in the safe zone 6/8: Slightly vulnerable, indicating one of the metrics may be off 4/8: Vulnerable, where multiple factors could indicate stress or lack of rest 2/8: Advanced risk, for multiple factors off the charts 0/8: Major risk, which indicates the requirement of medical attention The brand is also updating its app to allow tracking of potential symptoms. These features will roll out to all users of the Circular Ring and are promised to be available on the Ring 2, which was announced earlier this year and is up for pre-ordering via Kickstarter. Notably, Continuous has amassed pre-orders worth almost $4 million, which is 400 times the initial target. The campaign page says the sizing kits have already started to be shipped to backers, and delivery of the rings is expected to begin very soon. Follow
